Pfizer’s megablockbuster-to-be COVID pill Paxlovid scores FDA nod esagonowsky Wed, 12/22/2021 – 13:12 More: Pfizer's megablockbuster-to-be COVID pill Paxlovid scores FDA nod Source: fierce
read moreBiogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators aliu Wed, 12/22/2021 – 09:18 More: Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators Source: fierce
read moreParticulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavir fkansteiner Wed, 12/22/2021 – 09:15 More: Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavir Source: fierce
read moreWith Sanofi’s mighty Dupixent chasing behind, Takeda’s Eohilia suffers FDA rejection after mysterious delay aliu Wed, 12/22/2021 – 07:41 More: With Sanofi's mighty Dupixent chasing behind, Takeda's Eohilia suffers FDA rejection after mysterious delay Source: fierce
read moreCalls for booster vaccinations in order to combat the rising cases brought about by winter and the recent Omicron variant have intensified, in the midst of record case rates. More: Oxford and AstraZeneca aim to produce Omicron-targeted version of vaccine
read moreWith authorisation, Pfizer’s oral antiviral candidate Paxlovid is an investigational SARS-CoV-2 protease inhibitor could be prescribed at the first sign of COVID-19 infection. More: Pfizer to provide UK with additional 2.5 treatment courses of Paxlovid Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals